BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/2/2022 12:50:19 PM | Browse: 192 | Download: 531
 |
Received |
|
2022-07-13 16:10 |
|
Peer-Review Started |
|
2022-07-13 16:13 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-08-12 09:47 |
|
Revised |
|
2022-09-28 05:23 |
|
Second Decision |
|
2022-11-08 03:04 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2022-11-08 08:10 |
|
Articles in Press |
|
2022-11-08 08:10 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-11-04 12:55 |
|
Typeset the Manuscript |
|
2022-11-17 15:04 |
|
Publish the Manuscript Online |
|
2022-12-02 12:50 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
Effectiveness and safety of generic and brand direct acting antivirals for the treatment of chronic hepatitis C
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Maheeba Abdulla, Aysha Mohamed Al Ghareeb, Hamed Ali Hasan Yusuf Husain, Nafeesa Mohammed and Jehad AlQamish |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Maheeba Abdulla, MD, Doctor, Internal Medicine Department, Salmaniya Medical Complex, Arabian Gulf University, Rd No. 2904, Manama 2904, Bahrain. amaheeba@gmail.com |
| Key Words |
Hepatitis C virus; Direct acting antivirals; Generic; Brand; Sofosbuvir; Ombitasvir; Ledipasvir; Daclatasvir; Paritaprevir; Ritonavir; Dasabuvir; Ribavirin; Sustained virologic response |
| Core Tip |
World Health Organization aims to eliminate Hepatitis C virus (HCV) infection by 2030. Its guidelines recommend treatment for all individuals diagnosed with HCV infection >12 years. Management of HCV in low- and middle-income countries is hampered by high costs of medication. This is the first study to compare efficacy and safety of generic compared to original brand Direct Acting Antivirals (DAAs) for hepatitis C treatment in Bahrain, where the prevalence of HCV infection is estimated to be 1.7% (1.39 – 2.21%). Overall, our study adds to the literature on the similarity in effectiveness in patients receiving both brand and generic formulations of DAAs for chronic hepatitis C. |
| Publish Date |
2022-12-02 12:50 |
| Citation |
Abdulla M, Al Ghareeb AM, Husain HAHY, Mohammed N, Al Qamish J. Effectiveness and safety of generic and brand direct acting antivirals for the treatment of chronic hepatitis C. World J Clin Cases 2022; 10(34):12566-12577 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i34/12566.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i34.12566 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
